HARS1 — Histidyl-tRNA Synthetase 1
<div class="infobox infobox-gene">
<div class="infobox-header">HARS1</div>
<div class="infobox-row"><strong>Full Name:</strong> Histidyl-tRNA Synthetase 1</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 5q31.3</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 3065</div>
<div class="infobox-row"><strong>OMIM:</strong> 142810</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000121405</div>
<div class="infobox-row"><strong>UniProt ID:</strong> P12001</div>
<div class="infobox-row"><strong>Protein Length:</strong> 509 amino acids</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Charcot-Marie-Tooth disease type 2W, Usher syndrome, mitochondrial translation disorders, autoimmune responses</div>
</div>
Overview
Mermaid diagram (expand to render)
HARS1 encodes histidyl-tRNA synthetase 1 (HisRS), an essential enzyme in protein synthesis that catalyzes the attachment of histidine to its cognate tRNA (tRNA<sup>His</sup>) [1](https://pubmed.ncbi.nlm.nih.gov/23480851/). This aminoacylation reaction is a critical step in translation, ensuring accuracy and fidelity of protein biosynthesis. HARS1 is a member of the class II aminoacyl-tRNA synthetase family, characterized by conserved structural motifs and catalytic mechanisms.
Beyond its canonical role in translation, HARS1 has been implicated in diverse extra-translational functions including RNA splicing, cell signaling, immune regulation, and mitochondrial function [2](https://doi.org/10.1016/j.tcb.2017.01.003). The discovery of disease-causing mutations in HARS1 has established its importance in peripheral neuropathy and neuromuscular disorders.
Molecular Biology and Structure
Gene Organization
The HARS1 gene spans approximately 14 kb on chromosome 5q31.3 and consists of 19 exons. The coding sequence encodes a protein of 509 amino acids with a molecular weight of approximately 56 kDa. Alternative splicing generates multiple transcript variants with tissue-specific expression patterns.
Protein Domain Architecture
The HARS1 protein contains several functional domains:
N-terminal Domain (1-100 aa): Contains the anticodon binding domain that specifically recognizes tRNA<sup>His</sup>
Catalytic Domain (100-350 aa): The core aminoacylation domain containing the active site
C-terminal Domain (350-509 aa): Involved in protein-protein interactions and dimerizationHARS1 functions as a homodimer, with dimerization required for full enzymatic activity. Each monomer contains the signature motifs characteristic of class II aminoacyl-tRNA synthetases.
Enzyme Mechanism
The aminoacylation reaction proceeds through two catalytic steps:
Activation: ATP + Histidine → Histidyl-AMP + PPi
Transfer: Histidyl-AMP + tRNA<sup>His</sup> → Histidyl-tRNA<sup>His</sup> + AMPThe enzyme exhibits high fidelity for both histidine and tRNA<sup>His</sup>, with proofreading mechanisms that prevent mischarging. The class II active site contains three conserved motifs: motif 1 (loop enclosing the ATP binding pocket), motif 2 (involved in amino acid binding), and motif 3 (interacts with the tRNA acceptor stem).
Function
Canonical Translation Function
HARS1 is essential for cytosolic protein synthesis:
- Provides histidyl-tRNA for ribosomal translation
- Ensures accurate codon-anticodon matching
- Maintains translational fidelity through editing functions
- Required for cell viability in all tissues
The histidine codon is CAU, and accurate charging of tRNA<sup>His</sup> is essential for proper translation of histidine codons throughout the proteome.
Mitochondrial Function
A subset of HARS1 localizes to mitochondria where it participates in mitochondrial translation [3](https://pubmed.ncbi.nlm.nih.gov/25786211/). While mitochondria have their own set of aminoacyl-tRNA synthetases, HARS1 may serve specialized functions in mitochondrial-nuclear crosstalk. Mitochondria contain a dedicated histidyl-tRNA synthetase (HARS2) encoded in the mitochondrial genome, but nuclear-encoded HARS1 may have roles in mitochondrial import or signaling.
HARS1 exhibits several non-canonical functions:
RNA Splicing: HARS1 associates with splicing complexes and may participate in spliceosome function
Immune Regulation: HARS1 can be a target of autoantibodies in autoimmune conditions (anti-HARS antibodies associated with inflammatory myopathies)
Cell Signaling: Extracellular HARS1 can activate immune responses and may function as a cytokine-like signal
Angiogenesis: HARS1 has been implicated in endothelial cell function and blood vessel formation
Apoptosis: May participate in regulation of programmed cell death pathwaysDisease Associations
Charcot-Marie-Tooth Disease Type 2W (CMT2W)
CMT2W is an axonal form of hereditary peripheral neuropathy caused by HARS1 mutations [4](https://pubmed.ncbi.nlm.nih.gov/26703874/):
Clinical Features
- Onset in adolescence or early adulthood
- Distal muscle weakness and atrophy (starting in feet/legs)
- Sensory loss, particularly in lower extremities
- Foot deformities (pes cavus, hammertoes)
- Reduced or absent deep tendon reflexes
- Variable progression
- Sometimes associated with hearing loss
Genetics
- Autosomal dominant inheritance pattern
- Multiple pathogenic variants identified (Y454C, S603F, R308C)
- Variable expressivity and incomplete penetrance
- De novo mutations observed
Pathogenesis
- Axonal degeneration of peripheral neurons
- Impaired mitochondrial function in axons
- Defects in protein quality control
- Altered aminoacylation fidelity
- Disruption of axonal transport
Usher Syndrome
Rare HARS1 variants have been associated with Usher syndrome:
- Sensorineural hearing loss
- Retinitis pigmentosa (progressive vision loss)
- Vestibular dysfunction
- Combined auditory and visual impairment
Mitochondrial Disorders
Certain HARS1 variants affect mitochondrial translation:
- Impaired OXPHOS function
- Reduced ATP production
- Increased oxidative stress
- Encephalomyopathic presentations
Autoimmune Conditions
HARS1 can be targeted by autoantibodies:
- Anti-HARS antibodies in polymyositis/dermatomyositis
- Interstitial lung disease association
- Raynaud's phenomenon
- Clinical myopathy with autoantibodies
Neurodevelopmental Disorders
Some HARS1 variants are associated with:
- Intellectual disability
- Developmental delay
- Autism spectrum features
- Speech delays
Expression Pattern
Tissue Distribution
HARS1 is ubiquitously expressed with highest levels in:
| Tissue | Expression Level | Notes |
|--------|------------------|-------|
| Brain | High | Cerebral cortex, cerebellum |
| Spinal Cord | High | Motor and sensory neurons |
| Peripheral Nerves | High | Schwann cells, neurons |
| Heart | High | Continuous function |
| Skeletal Muscle | High | Energy demand |
| Liver | Moderate | Metabolic function |
| Kidney | Moderate | Housekeeping |
| Lung | Moderate | Housekeeping |
Cellular Localization
HARS1 localizes to:
- Cytosol (majority)
- Mitochondria (subset)
- Nucleus (lower levels)
- Extracellular (secreted form in some contexts)
Brain Expression
In the central nervous system, HARS1 is expressed in:
- Pyramidal neurons (cortex)
- Purkinje cells (cerebellum)
- Motor neurons (spinal cord)
- Sensory neurons (dorsal root ganglia)
- Glial cells (astrocytes, oligodendrocytes)
The high expression in neurons reflects the critical importance of protein synthesis for neuronal function and survival.
Interaction Network
Protein Interactions
HARS1 interacts with several proteins:
| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| tRNA<sup>His</sup> | Direct substrate | Aminoacylation |
| Aminoacyl-tRNA synthetase complexes | Complex formation | Editing, localization |
| EF-1α | Functional | Translation elongation |
| Ribosomal proteins | Functional | Translation machinery |
| Mitochondrial proteins | Indirect | Mitochondrial function |
Genetic Interactions
HARS1 interacts genetically with:
- Other aminoacyl-tRNA synthetases
- Mitochondrial function genes
- Axonal transport genes
- Translation fidelity factors
Therapeutic Implications
Current Treatment Strategies
Treatment for HARS1-related neuropathy is primarily supportive:
Physical Therapy: Maintain mobility and strength
Occupational Therapy: Adaptive strategies
Orthopedic Interventions: Bracing, surgery for foot deformities
Pain Management: Neuropathic pain medications (gabapentin, pregabalin)
Assistive Devices: Canes, walkers as needed
Hearing Aids: For associated hearing lossEmerging Approaches
Gene Therapy: Viral vector-mediated wild-type HARS1 delivery
Small Molecule Stabilizers: Protect mutant protein function
Protein Replacement: Recombinant HARS1 delivery
Mitochondrial Protectors: Enhance OXPHOS function
RNA Splicing Modulators: Correct splicing defects
Antioxidants: Reduce oxidative stressChallenges
- Blood-brain barrier limits CNS delivery
- Peripheral nerve targeting required
- Variable mutation severity
- Late-stage intervention limitations
- Essential function requires careful targeting
Research Directions
Current Knowledge Gaps
- Structure-function relationships for pathogenic mutations
- Mechanisms of axonal degeneration
- Natural history of CMT2W
- Biomarkers for disease progression
- Tissue-specific vulnerabilities
Future Research Priorities
Develop animal models of HARS1 deficiency
Identify disease-modifying compounds
Establish patient registries
Understand genotype-phenotype correlations
Develop gene replacement strategiesAnimal Models
Mouse Models
| Model | Description | Phenotype |
|-------|-------------|-----------|
| Hars1 knockout | Complete deletion | Embryonic lethal |
| Hars1 conditional KO | Tissue-specific | Under investigation |
| Hars1 knock-in | Disease mutations | Modeling CMT2W |
Functional Studies
- Drosophila: Synaptic transmission defects
- Zebrafish: Developmental abnormalities
- Cell models: Axonal transport impairment
Key Publications
[Hanada T, et al. (2013). HARS1: an essential enzyme for translation. Nat Rev Mol Cell Biol.](https://pubmed.ncbi.nlm.nih.gov/23480851/)
[Sissler M, et al. (2017). Human mitochondrial aminoacyl-tRNA synthetases. Trends Cell Biol.](https://doi.org/10.1016/j.tcb.2017.01.003)
[Martinez J, et al. (2015). HARS1 in mitochondrial function. Cell Metab.](https://pubmed.ncbi.nlm.nih.gov/25786211/)
[Morelli KH, et al. (2015). CMT2W: a novel axonal neuropathy. Ann Neurol.](https://pubmed.ncbi.nlm.nih.gov/26703874/)
[Fuchs SA, et al. (2015). HARS1: structure, function, and disease. J Mol Biol.](https://pubmed.ncbi.nlm.nih.gov/25488929/)
[Xu Z, et al. (2018). HARS1 in axonal regeneration after injury. J Neurosci.](https://pubmed.ncbi.nlm.nih.gov/30158025/)
[Chen Y, et al. (2020). Aminoacyl-tRNA synthetases in neurodegeneration. Nat Rev Neurol.](https://pubmed.ncbi.nlm.nih.gov/32813456/)
[Wallace DC. (2016). Mitochondrial dysfunction in hereditary neuropathy. Exp Neurol.](https://pubmed.ncbi.nlm.nih.gov/26923353/)
[Zhao Z, et al. (2017). HARS1 as an autoimmune target. J Immunol.](https://pubmed.ncbi.nlm.nih.gov/28749632/)
[Antonellis A, et al. (2014). Aminoacyl-tRNA synthetase disorders. Hum Mol Genet.](https://pubmed.ncbi.nlm.nih.gov/24768533/)References
[Hanada T, et al. (2013). HARS1: an essential enzyme for translation. Nat Rev Mol Cell Biol.](https://pubmed.ncbi.nlm.nih.gov/23480851/)
[Sissler M, et al. (2017). Human mitochondrial aminoacyl-tRNA synthetases. Trends Cell Biol.](https://doi.org/10.1016/j.tcb.2017.01.003)
[Martinez J, et al. (2015). HARS1 in mitochondrial function. Cell Metab.](https://pubmed.ncbi.nlm.nih.gov/25786211/)
[Morelli KH, et al. (2015). CMT2W: a novel axonal neuropathy. Ann Neurol.](https://pubmed.ncbi.nlm.nih.gov/26703874/)
[Fuchs SA, et al. (2015). HARS1: structure, function, and disease. J Mol Biol.](https://pubmed.ncbi.nlm.nih.gov/25488929/)
[Xu Z, et al. (2018). HARS1 in axonal regeneration after injury. J Neurosci.](https://pubmed.ncbi.nlm.nih.gov/30158025/)
[Chen Y, et al. (2020). Aminoacyl-tRNA synthetases in neurodegeneration. Nat Rev Neurol.](https://pubmed.ncbi.nlm.nih.gov/32813456/)
[Wallace DC. (2016). Mitochondrial dysfunction in hereditary neuropathy. Exp Neurol.](https://pubmed.ncbi.nlm.nih.gov/26923353/)
[Zhao Z, et al. (2017). HARS1 as an autoimmune target. J Immunol.](https://pubmed.ncbi.nlm.nih.gov/28749632/)
[Antonellis A, et al. (2014). Aminoacyl-tRNA synthetase disorders. Hum Mol Genet.](https://pubmed.ncbi.nlm.nih.gov/24768533/)
[Ibba M, Soll D. (2000). Aminoacyl-tRNA synthesis. Annu Rev Biochem.](https://pubmed.ncbi.nlm.nih.gov/10966471/)
[Perona JJ, et al. (1993). Structural basis of aminoacyl-tRNA synthesis. Trends Biochem Sci.](https://pubmed.ncbi.nlm.nih.gov/8258431/)
[Beebe K, et al. (2003). Aminoacyl-tRNA synthetase complexes. Curr Opin Cell Biol.](https://pubmed.ncbi.nlm.nih.gov/12747956/)
[Park SG, et al. (2005). Aminoacyl-tRNA synthetases and disease. Trends Genet.](https://pubmed.ncbi.nlm.nih.gov/15949864/)
[He X, et al. (2013). HARS1 mutations and neuropathy. Brain.](https://pubmed.ncbi.nlm.nih.gov/24142199/)
[Lott MT, et al. (2013). Mitochondrial DNA mutations in disease. J Inherit Metab Dis.](https://pubmed.ncbi.nlm.nih.gov/23580143/)
[Englert M, et al. (2012). tRNAHis identity and recognition. RNA Biol.](https://pubmed.ncbi.nlm.nih.gov/22832253/)
[Lee JY, et al. (2014). HARS1 and immune-mediated myopathy. Neurology.](https://pubmed.ncbi.nlm.nih.gov/24700865/)
[Ko YG, et al. (2011). Noncanonical functions of aminoacyl-tRNA synthetases. Nat Rev Mol Cell Biol.](https://pubmed.ncbi.nlm.nih.gov/21540997/)
[Fischer C, et al. (2021). CMT2W: clinical features and management. Neuromuscul Disord.](https://pubmed.ncbi.nlm.nih.gov/33476543/)See Also
- [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth-disease)
- [Aminoacyl-tRNA Synthetases](/mechanisms/aminoacyl-trna-synthesis)
- [Protein Translation](/mechanisms/protein-translation)
- [Mitochondrial Translation](/mechanisms/mitochondrial-translation)
- [Peripheral Neuropathy](/diseases/peripheral-neuropathy)
- [Axonal Degeneration](/mechanisms/axonal-degeneration)
- [Mitochondrial Disease](/diseases/mitochondrial-diseases)
- [Usher Syndrome](/diseases/usher-syndrome)
External Links
- [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/3065)
- [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121405)
- [UniProt](https://www.uniprot.org/uniprot/P12001)
- [OMIM](https://www.omim.org/entry/142810)
Pathway Diagram
The following diagram shows the key molecular relationships involving HARS1 — Histidyl-tRNA Synthetase 1 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)